Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSC), has entered an agreement to grant Novo Nordisk a non-exclusive right to use its iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.
Novo Nordisk will have a non-exclusive license to use the iPSC cell lines for research and development purposes, and to utilize GMP-grade cell lines for clinical and commercial manufacture and commercialization of iPSC-derived cell therapies. Terms of the agreement were not disclosed.
